Vensun Pharmaceuticals develops a portfolio of generic prescription products in various dosage forms across a broad range of therapeutic categories. The company co-develops products with strategic partners in the U.S. and overseas and has in‑licensed over 25 products to expand its pipeline. Vensun has four ANDAs approved, more than 15 filed ANDAs, and approximately 15 products in active development with partners. The company completed a $22.5 million Series C financing to support research and development and working capital needs. Management said the financing will enable Vensun to transform its development pipeline into approved commercial products and pursue additional growth opportunities. Perceptive Advisors noted Vensun expects a number of new product approvals over the next several years, positioning the company for continued growth. Vensun Pharmaceuticals, Inc. is a private generic pharmaceutical company focused on developing a portfolio of complex generic prescription products across various dosage forms. The company co-develops products with multiple strategic partners in the U.S. and overseas. Vensun has over 40 products in active development and multiple ANDAs on file with the FDA. Management expects several approvals and product launches in 2014. The Series B financing is intended to increase the number of products under development and to explore additional in-license opportunities. The company targets a broad range of therapeutic categories through its partner-based development model.

Total raised

$38M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2016